Moderator of 1 Session
Presenter of 3 Presentations
CHAIR INTRODUCTION (ID 2080)
CLINICAL STUDIES OF THE ASSOCIATION BETWEEN TOXOPLASMOSIS AND MENTAL DISEASES (ID 1494)
PRE-RECORDED: REQUIREMENTS FOR CLINICAL TRIALS OF A VACCINE CANDIDATE FOR HUMAN TOXOPLASMOSIS (ID 1803)
Abstract
Abstract Body
We have now many promising vaccine candidates for toxoplasmosis that can be assayed in human clinical trials. They have been evaluated in different animal models, including mice, rabbit and monkeys, achieving diverse levels of protection. The more promising are vaccines based on live attenuated parasites and total antigen preparations or subunit vaccine (selected protein fragments obtained through recombinant protein methodology or expressed through nucleic acid vaccine based platforms). Clinical trials in human could have as primary outcome the reduction of congenital toxoplasmosis in non-immune human populations or the reduction of new chorioretinal scars. Secondary outcomes could be the induction of specific CD8+ T cells and CD4+ specific memory cells. I will discuss during this conference the main challenges and barriers to launch human clinical trial for toxoplasmosis.